

566	Unknown †	Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
		Condition: Leukemia
		Intervention: Biological: autologous tumor cell vaccine
567	Terminated	Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
		Condition: Melanoma (Skin)
		Interventions: Biological: MART-1 antigen; Biological: aldesleukin; Biological: gp100 antigen; Biological: recombinant CD40-ligand; Biological: recombinant interferon gamma; Biological: recombinant interleukin-4; Biological:
568	Completed	Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
		Condition: Prostate Cancer
		Intervention: Biological: Dendritic Cells (DC) prostate
569	Completed	A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL
		Conditions: Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Warts; Human Papillomavirus Infection
		Interventions: Biological: V504; Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
570	Active, not recruiting	Proteome-based Immunotherapy of Brain Metastases From Breast Cancer
		Condition: Neoplasm Metastasis
		Interventions: Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes; Biological: Dendritic
571	Active, not recruiting	Proteome-based Immunotherapy of Lung Cancer Brain Metastases
		Condition: Neoplasm Metastasis
		Interventions: Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes; Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
572	Completed	Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
		Condition: Lymphoma
		Interventions: Biological: aldesleukin; Biological: autologous tumor cell vaccine
573	Completed	Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
		Condition: Cervical Cancer
		Intervention: Biological: Gardasil® HPV vaccine
574	Completed	Tumor RNA Transfected Dendritic Cell Vaccines
		Condition: Prostate Cancer
		Intervention: Biological: Tumor RNA transfected dendritic cells
575	Completed	Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase 1/2)
		Condition: Pancreatic Cancer
		Interventions: Biological: VEGFR1-1084, VEGFR2-169; Drug: Gemcitabine
576	Completed	Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
		Condition: Esophageal Cancer
		Intervention: Biological: URLC10, VEGFR1 and VEGFR2
577	Completed	Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
		Condition: Esophageal Cancer
		Intervention: Biological: URC10, TTK, KOC1
578	Completed	Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

		Condition:	Gastric Cancer
		Intervention:	Biological: URLC10, VEGFR1 and VEGFR2
579	Completed	Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer	
		Condition:	Gastric Cancer
		Intervention:	Biological: URLC10, KOC1, VEGFR1 and VEGFR2
580	Completed	Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype	
		Conditions:	B Cell Lymphoma; Follicular Lymphoma; Neoplasm
		Interventions:	Drug: Id-KLH Vaccine; Drug: QS-21 (Stimulation-QS-21) Drug
581	Completed	Vaccine Therapy in Treating Patients With Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: dendritic cell-MART-1 peptide vaccine; Biological: gp100 antigen; Biological: therapeutic tumor infiltrating lymphocytes; Biological: tyrosinase peptide
582	Terminated	Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer	
		Condition:	Breast Cancer
		Intervention:	Biological: TTK peptide mixed with Montanide ISA 51
583	Unknown †	Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer	
		Condition:	Non Small Cell Lung Cancer
		Intervention:	Biological: URLC10, TTK and KOC1
584	Unknown †	Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer	
		Condition:	Non Small Cell Lung Cancer
		Intervention:	Biological: URLC10, VEGFR1 and VEGFR2
585	Completed	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: PADRE 965.10; Biological: alpha-type-1 polarized dendritic cells; Biological: keyhole limpet
586	Active, not recruiting	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	
		Condition:	Malignant Neoplasms of Brain
		Interventions:	Biological: tetanus toxoid; Biological: therapeutic autologous dendritic cells; Biological: therapeutic autologous lymphocytes
587	Recruiting	Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer	
		Conditions:	Fallopian Tubes; Ovarian Cancer; Peritoneal Cancer
		Intervention:	Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
588	Active, not recruiting	Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia	
		Condition:	Leukemia
		Interventions:	Biological: GM-K562 cell vaccine; Drug: imatinib mesylate
589	Active, not recruiting	Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma	
		Conditions:	Sarcoma, Clear Cell; Sarcoma, Alveolar Soft Part; Renal Cell Carcinoma; Melanoma
		Intervention:	Biological: GVAX
590	Completed	Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	

		Conditions:	Intraocular Melanoma; Melanoma (Skin)
		Intervention:	Biological: mouse gp100 plasmid DNA vaccine
591	Recruiting	Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of	
		Condition:	Malignant Pleural Mesothelioma
		Interventions:	Biological: WT-1-vaccine Montanide + GM-CSF; Biological: Montanide adjuvant + GM-CSF
592	Recruiting	Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk	
		Condition:	Neuroblastoma
		Intervention:	Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
593	Terminated	Influenza Vaccine Post Allogeneic Transplant	
		Conditions:	Hematopoietic Stem Cell Transplant; Hematologic Malignancy
		Intervention:	Biological: Influenza vaccine
594	Unknown †	Multiple-Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer	
		Condition:	Non Small Cell Lung Cancer
		Intervention:	Biological: HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2
595	Completed	Alternate Dosing Schedules Study for HPV Vaccine	
		Conditions:	Cervical Cancer; Genital Warts
		Intervention:	
596	Completed	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: autologous tumor cell vaccine; Biological: therapeutic autologous dendritic cells
597	Completed	Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy	
		Conditions:	Lymphoma; Multiple Myeloma; Influenza A Virus, H1N1 Subtype
		Intervention:	Biological: AS03-adjuvanted H1N1 pandemic influenza vaccine
598	Completed	Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)	
		Conditions:	Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Warts; Human Papillomavirus Infection
		Interventions:	Biological: Comparator: V505 formulation 1; Drug: Comparator: V505 formulation 2; Biological: Comparator:
599	Recruiting	Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients	
		Condition:	Melanoma
		Interventions:	Biological: 2 vaccine injections in 1 limb; Biological: 2 vaccine injections in different limbs; Biological: 2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4
600	Completed	MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or	
	Has	Conditions:	Melanoma; Metastases
		Interventions:	Drug: MDX-010 (anti-CTLA4) monoclonal antibody; Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
601	Unknown †	Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	
		Condition:	Esophageal Cancer
		Intervention:	Biological: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil
602	Recruiting	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours	
		Condition:	Herpes Zoster

		Interventions:	Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Drug: Placebo
603	Active, not recruiting	Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls	
		Conditions:	Cervical Cancer; HPV Type 16/18 Infections
		Intervention:	Biological: GSK Biologicals' HPV vaccine 580299
604	Unknown †	Vaccine Therapy in Treating Patients With Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: autologous tumor cell vaccine; Biological: therapeutic autologous dendritic cells
605	Completed	Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers	
		Conditions:	Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML)
		Interventions:	Biological: WT1:126-134 Peptide; Biological: PR1:169-177 Peptide; Drug: WT1 and PR1 Peptide Vaccines; Drug: GM-CSF (Sargramostim); Biological: WT1 and PR1 Peptide Vaccines
606	Completed	Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female	
	Has	Conditions:	Human Papillomavirus Infection; Cervical Intraepithelial Neoplasia; Papillomavirus Vaccines
		Interventions:	Biological: Boostrix ® Polio; Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
607	Completed	Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With	
		Conditions:	Recurrent Melanoma; Stage IV Melanoma
		Interventions:	Drug: cyclophosphamide; Drug: fludarabine phosphate; Biological: therapeutic autologous lymphocytes;
608	Recruiting	Cholecalciferol and Flu Vaccine in Treating Healthy Participants	
		Condition:	Healthy, no Evidence of Disease
		Interventions:	Dietary Supplement: cholecalciferol; Other: questionnaire administration; Biological: trivalent influenza vaccine
609	Completed	Vaccine Therapy in Treating Patients With Metastatic Melanoma	
		Conditions:	Intraocular Melanoma; Melanoma (Skin)
		Interventions:	Biological: MART-1 antigen; Biological: gp100:209-217(210M) peptide vaccine; Biological: therapeutic autologous
610	Completed	Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma	
		Conditions:	Recurrent Melanoma; Stage IV Melanoma
		Interventions:	Biological: aldesleukin; Biological: gp100:209-217(210M) peptide vaccine; Other: laboratory biomarker analysis
611	Active, not recruiting	Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma	
		Condition:	Metastatic Malignant Melanoma
		Interventions:	Biological: Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell
612	Terminated	Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma	
		Condition:	Lymphoma
		Interventions:	Biological: Hodgkin's antigens-GM-CSF-expressing cell vaccine; Procedure: adjuvant therapy
613	Terminated	Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma	
	Has	Condition:	Lymphoma
		Interventions:	Biological: autologous tumor cell vaccine; Biological: keyhole limpet hemocyanin; Biological: sargramostim; Procedure: adjuvant therapy
614	Completed	Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: MART-1:27-35 peptide vaccine; Biological: aldesleukin; Biological: filgrastim; Biological: incomplete Freund's adjuvant; Biological: therapeutic autologous lymphocytes; Biological: therapeutic tumor infiltrating

615	Completed	Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 – 25 Years of Age.	
	Has	Conditions:	HPV-16/18 Infections; Cervical Neoplasia
616	Active, not recruiting	Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer	
		Condition:	Colorectal Cancer
617	Completed	Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18	
		Interventions:	Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope); Device: Derma Vax (electroporation device); Biological: GM-CSF; Drug: Cyclophosphamide
618	Suspended	Interventions:	Biological: Cervarix™; Biological: Placebo vaccine (Al(OH) ₃)
		Condition:	Lymphoma
619	Unknown †	GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With	
		Interventions:	Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: rituximab; Drug: sargramostim; Drug: vincristine; Procedure:
620	Completed	Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma	
		Interventions:	Biological: MAGE-10.A2; Biological: MART-1 antigen; Biological: NY-ESO-1 peptide vaccine; Biological:
621	Recruiting	Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma	
		Interventions:	Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: recombinant interleukin-12; Biological: tyrosinase peptide
622	Completed	Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI	
		Interventions:	Biological: GM-K562 cell vaccine; Biological: recombinant interferon alfa; Biological: sargramostim
623	Active, not recruiting	Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer	
		Intervention:	Biological: GSK Biologicals' 719125
624	Recruiting	A Study of V503 in Preadolescents and Adolescents (V503-002 EXT1 EXT2)	
		Intervention:	Biological: V503
625	Active, not recruiting	Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma	
		Intervention:	Biological: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
626	Active, not recruiting	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16 to 26-Year-Old Women (V503-001 AM2)	
		Interventions:	Biological: Comparator: GARDASIL(R); Biological: Experimental: V503
626	Active, not recruiting	Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)

627	Terminated	Interventions:	Biological: incomplete Freund's adjuvant; Biological: melanoma helper peptide vaccine; Biological: multi-epitope Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
		Condition:	Sarcoma
		Interventions:	Biological: NY-ESO-1 peptide vaccine; Biological: sargramostim
628	Withdrawn	Interventions:	DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer
		Conditions:	Ovarian Cancer; Primary Peritoneal Cancer
		Intervention:	Biological: DCVax-L and T Cells
629	Recruiting	Interventions:	A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
		Condition:	Cervical Intraepithelial Neoplasia
		Interventions:	Biological: VGX 3100; Biological: Placebo
630	Withdrawn	Interventions:	Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
		Conditions:	Colorectal Neoplasms; Anal, Colon, and Rectal Cancers
		Interventions:	Biological: Autologous tumor cell + CpG vaccine; Procedure: Autologous hematopoietic and immune cell rescue (transplantation)
631	Terminated Has	Interventions:	Vaccine Treatment of Kidney Cancer
		Condition:	Kidney Cancer
		Interventions:	Drug: 117-126:Fibroblast growth factor 5 (FGF-5); Drug: Fibroblast growth factor 5 (FGF-5):172-176/217-220; Other: IL-2
632	Completed Has	Interventions:	Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of
		Condition:	HPV-16/18 Infections and Cervical Neoplasia
		Intervention:	Biological: Cervarix TM
633	Terminated Has	Interventions:	RNAActive®-Derived Therapeutic Vaccine
		Condition:	Hormone Refractory Prostate Cancer
		Intervention:	Biological: CV9103
634	Completed	Interventions:	A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
		Condition:	Breast Cancer
		Intervention:	Biological: MVA-BN-HER2
635	Completed	Interventions:	Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
		Conditions:	Melanoma (Skin); Intraocular Melanoma
		Interventions:	Biological: Xenogeneic Tyrosinase DNA Vaccine; Device: TriGrid Delivery System for Intramuscular Electroporation
636	Unknown †	Interventions:	Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
		Condition:	Lymphoma
		Interventions:	Biological: Hodgkin's antigens-GM-CSF-expressing cell vaccine; Biological: filgrastim; Biological: rituximab; Drug: cyclophosphamide
637	Completed	Interventions:	A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
		Conditions:	HPV-16 Infection; Associated Cervical Neoplasia; HPV-18 Infection
		Intervention:	Biological: HPV-16/18 L1 VLP AS04
638	Recruiting	Interventions:	Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
		Conditions:	Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia

		Intervention:	Biological: V503 Vaccine
639	Active, not recruiting Has	An Investigational Study of Gardasil™ (dHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020 AM4, EXT1, EXT2 [AM1])	
		Condition:	Condylomata Acuminata
		Interventions:	Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Biological: Comparator:
640	Recruiting	Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma	
		Condition:	Glioblastoma
		Interventions:	Drug: Cyclophosphamide; Biological: IMA950 plus GM-CSF; Biological: IMA950; Drug: Imiquimod
641	Completed Has	Safety Study to Evaluate FluMist in Immunocompromised Children	
		Condition:	Cancer
		Interventions:	Biological: FluMist; Biological: Placebo
642	Completed Has	Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix™) in HIV Infected Females	
		Conditions:	HPV-16/18 Infections; Cervical Neoplasia
		Interventions:	Biological: Cervarix™; Biological: Placebo Control
643	Recruiting	Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme	
		Condition:	Recurrent Central Nervous System Neoplasm
		Intervention:	Biological: BTSC mRNA-loaded DCs
644	Completed	Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: NY-ESO-1 peptide vaccine; Biological: aldesleukin; Biological: filgrastim; Biological: incomplete Freund's adjuvant; Biological: therapeutic autologous lymphocytes; Drug: cyclophosphamide; Drug: fludarabine phosphate
645	Recruiting	Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating	
		Condition:	Multiple Myeloma
		Interventions:	Biological: aMILs; Biological: Allogeneic Myeloma Vaccine
646	Active, not recruiting	Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in	
		Condition:	Breast Cancer
		Intervention:	Biological: Autologous, Lethally Irradiated Breast Cancer Cells
647	Completed Has	Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women	
		Conditions:	Papillomavirus Type 16/18 Infection; Cervical Intraepithelial Neoplasia
		Intervention:	Biological: Cervarix™
648	Active, not recruiting Has	Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects	
		Condition:	Prophylaxis for HPV Infections and Associated Cervical Neoplasia.
		Interventions:	Biological: HPV GSK 580299 vaccine; Biological: Placebo control
649	Active, not recruiting	GARDASIL™ Vaccine Impact in Population Study	
		Condition:	Human Papillomavirus Infections
		Intervention:	
650	Unknown †	Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes	
		Condition:	Myelodysplastic Syndromes

651	Completed	Interventions:	Biological: GM-K562 cell vaccine; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization;
		Condition:	Pancreatic Cancer
652	Recruiting	Intervention:	Biological: vitespen
		Condition:	Metastatic Breast Cancer
		Intervention:	Biological: hTERT
653	Active, not recruiting	Condition:	Non-small Cell Lung Cancer
		Interventions:	Biological: cyclophosphamide + EMD531444 + BSC; Biological: Saline + Placebo + BSC
654	Completed	Conditions:	Human Papillomavirus; Infection
		Intervention:	
655	Completed	Conditions:	Esophageal Cancer; Gastric Cancer
		Interventions:	Biological: G17DT Immunogen; Drug: cisplatin; Drug: fluorouracil
656	Unknown †	Condition:	Melanoma (Skin)
		Interventions:	Biological: HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine; Biological:
657	Completed	Condition:	Melanoma
		Interventions:	Biological: Autologous, DNP-modified vaccine (M-Vax); Biological: Autologous, DNP-Modified Melanoma Vaccine; Biological: Autologous, DNP-Modified Vaccine
658	Completed Has	Condition:	Prostate Cancer
		Interventions:	Biological: sipuleucel-T; Biological: Placebo
659	Completed	Condition:	Multiple Myeloma and Plasma Cell Neoplasm
		Interventions:	Biological: aldesleukin; Biological: idiotype-pulsed autologous dendritic cell vaccine APC8020; Biological:
660	Recruiting	Condition:	Lymphoma
		Interventions:	Biological: plasmid DNA vaccine therapy; Other: flow cytometry; Other: immunoenzyme technique
661	Completed	Conditions:	Stage IV Melanoma; Stage III Melanoma; Recurrent Melanoma
		Interventions:	Drug: dendritic cell-gp100-MART-1 antigen vaccine; Drug: sargramostim
662	Unknown †	Condition:	Head and Neck Cancer
		Interventions:	Biological: Ad5F35-LMP1/LMP2-transduced autologous dendritic cells; Drug: celecoxib; Other: flow cytometry;
663	Unknown †	Condition:	Melanoma (Skin)

664	Completed	Interventions:	Biological: HPV 16 E7:12-20 peptide vaccine; Biological: gp100 antigen; Biological: incomplete Freund's
		Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer	
		Condition:	Cervical Cancer
665	Active, not recruiting	Interventions:	Biological: human papillomavirus 16 E7 peptide; Biological: synthetic human papillomavirus 16 E6 peptide; Procedure: adjuvant therapy; Procedure: surgical procedure; Radiation: radiation therapy
		Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents	
		Condition:	Human Papillomavirus (HPV) Infection
666	Completed	Interventions:	Biological: GSK Biologicals' HPV Vaccine GSK580299; Biological: Enderix-B™
		Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
667	Active, not recruiting	Interventions:	Biological: human gp100 plasmid DNA vaccine; Biological: mouse gp100 plasmid DNA vaccine
		HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM	
		Condition:	Brain and Central Nervous System Tumors
668	Completed	Intervention:	Biological: HSPPC-96
		Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery	
		Condition:	Melanoma (Skin)
669	Recruiting	Interventions:	Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: sargramostim; Biological:
		Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558	
		Condition:	Melanoma (Skin)
670	Unknown †	Interventions:	Biological: MART-1; Biological: NY-ESO-1; Biological: gp100:209-217(210M); Biological: gp100:280-288(288V); Drug: Montanide ISA 51 VG; Biological: BMS-936558
		Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV	
		Condition:	Melanoma (Skin)
671	Unknown †	Interventions:	Biological: incomplete Freund's adjuvant; Biological: melanoma helper peptide vaccine; Biological: multi-epitope
		Immunization Against Tumor Cells in Sezary Syndrome	
		Conditions:	Cutaneous T-Cell Lymphoma; Sezary Syndrome
672	Completed	Intervention:	Biological: Autologous Dendritic Cell Vaccine
		Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells	
		Condition:	Breast Cancer
673	Unknown †	Intervention:	Biological: HER2 CTL vaccine (plus trastuzumab)
		Vaccine Therapy in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
674	Completed	Intervention:	Biological: recombinant vaccinia-TRICOM vaccine
		Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A	
		Condition:	Melanoma
675	Recruiting	Intervention:	Biological: GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)
		Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer	
		Condition:	Prostate Cancer
676	Completed	Interventions:	Biological: pTVG-HP; Biological: rhGM-CSF
		A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer	
		Conditions:	Neoplasms; Breast Cancer
		Intervention:	Biological: Immunotherapeutic SB719125 (Primary)

677	Completed	A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer	
		Condition:	Carcinoma, Renal Cell
678	Completed	Vaccine Therapy in Treating Patients With Liver Cancer	
		Condition:	Liver Cancer
679	Terminated	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma	
		Interventions:	Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological:
680	Terminated	Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer	
		Intervention:	Biological: therapeutic autologous dendritic cells
681	Completed	Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma	
		Intervention:	Biological: dendritic cell-MART-1 peptide vaccine
682	Active, not recruiting	Vaccine Therapy in Treating Patients With Malignant Glioma	
		Intervention:	Biological: therapeutic autologous dendritic cells
683	Recruiting	BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA	
		Interventions:	Biological: bevacizumab; Biological: emepepimut-S; Drug: carboplatin; Drug: cyclophosphamide; Drug: paclitaxel; Radiation: radiation therapy
684	Completed	Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma	
		Interventions:	Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological:
685	Completed	Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer	
		Interventions:	Biological: therapeutic autologous dendritic cells; Procedure: conventional surgery
686	Active, not recruiting	Proteome-based Personalized Immunotherapy of Glioblastoma	
		Interventions:	Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes; Biological: Dendritic
687	Unknown †	Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer	
		Intervention:	Biological: MUC1 antigen/SB AS-2
688	Completed	Vaccination for Patients With High Risk Cancers of the Blood	
		Intervention:	Drug: WR 1 and PR 1 Peptide Vaccine
689	Unknown †	Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small	
		Condition:	Non Small Cell Lung Cancer